TraffikGene
TraffikGene is a biotech company focused on developing a proprietary non-viral gene delivery technology platform to overcome the limitations of nucleic acid therapeutics (NATs). Their platform utilizes short, synthetic peptide scaffolds that can be robotically synthesized and scaled, allowing for the delivery of various nucleic acid payloads like mRNA, siRNA, DNA, and CRISPR/Cas. The technology offers precise targeting through physicochemical and molecular approaches, maximizes efficacy while avoiding toxicity, and is designed to be non-immunogenic, enabling repeat dosing. TraffikGene's approach facilitates carrier discovery and optimization through high-throughput screening and machine learning, with applications in vaccination, immunotherapy, and rare diseases. They are actively seeking partnerships for in-licensing their delivery technology.
TraffikGene
TraffikGene is a biotech company focused on developing a proprietary non-viral gene delivery technology platform to overcome the limitations of nucleic acid therapeutics (NATs). Their platform utilizes short, synthetic peptide scaffolds that can be robotically synthesized and scaled, allowing for the delivery of various nucleic acid payloads like mRNA, siRNA, DNA, and CRISPR/Cas. The technology offers precise targeting through physicochemical and molecular approaches, maximizes efficacy while avoiding toxicity, and is designed to be non-immunogenic, enabling repeat dosing. TraffikGene's approach facilitates carrier discovery and optimization through high-throughput screening and machine learning, with applications in vaccination, immunotherapy, and rare diseases. They are actively seeking partnerships for in-licensing their delivery technology.